BlackRock’s Matinas BioPharma MTNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $30.8K | Buy |
3,351
+41
| +1% | +$396 | ﹤0.01% | 5285 |
|
|
2026
Q1 | $24.8K | Hold |
3,310
| – | – | ﹤0.01% | 5269 |
|
|
2025
Q4 | $29.1K | Hold |
3,310
| – | – | ﹤0.01% | 5155 |
|
|
2025
Q3 | $93.8K | Hold |
3,310
| – | – | ﹤0.01% | 4847 |
|
|
2025
Q2 | $44.2K | Hold |
3,310
| – | – | ﹤0.01% | 5012 |
|
|
2025
Q1 | $25.8K | Hold |
3,310
| – | – | ﹤0.01% | 5053 |
|
|
2024
Q4 | $25.3K | Hold |
3,310
| – | – | ﹤0.01% | 5064 |
|
|
2024
Q3 | $176K | Hold |
3,310
| – | – | ﹤0.01% | 4557 |
|
|
2024
Q2 | $393K | Hold |
3,310
| – | – | ﹤0.01% | 4405 |
|
|
2024
Q1 | $673K | Sell |
3,310
-25
| -0.7% | -$4.45K | ﹤0.01% | 4301 |
|
|
2023
Q4 | $541K | Hold |
3,335
| – | – | ﹤0.01% | 4409 |
|
|
2023
Q3 | $325K | Sell |
3,335
-9
| -0.3% | -$1.66K | ﹤0.01% | 4547 |
|
|
2023
Q2 | $903K | Buy |
3,344
+53
| +2% | +$18.5K | ﹤0.01% | 4316 |
|
|
2023
Q1 | $1.16M | Sell |
3,291
-331
| -9% | -$125K | ﹤0.01% | 4284 |
|
|
2022
Q4 | $1.36M | Sell |
3,622
-2,083
| -37% | -$1.04M | ﹤0.01% | 4304 |
|
|
2022
Q3 | $2.72M | Sell |
5,705
-88
| -2% | -$51.8K | ﹤0.01% | 4034 |
|
|
2022
Q2 | $3.43M | Buy |
5,793
+26
| +0.5% | +$14.9K | ﹤0.01% | 3983 |
|
|
2022
Q1 | $3.48M | Buy |
5,767
+40
| +0.7% | +$22.1K | ﹤0.01% | 4141 |
|
|
2021
Q4 | $4.34M | Buy |
5,727
+2,095
| +58% | +$1.68M | ﹤0.01% | 4053 |
|
|
2021
Q3 | $3.54M | Buy |
3,632
+30
| +0.8% | +$19.4K | ﹤0.01% | 4074 |
|
|
2021
Q2 | $2.09M | Sell |
3,602
-632
| -15% | -$407K | ﹤0.01% | 4249 |
|
|
2021
Q1 | $3.33M | Buy |
4,234
+1,242
| +42% | +$1.25M | ﹤0.01% | 4116 |
|
|
2020
Q4 | $3.05M | Buy |
2,992
+9
| +0.3% | +$6.25K | ﹤0.01% | 3891 |
|
|
2020
Q3 | $1.71M | Buy |
2,983
+44
| +1% | +$26.2K | ﹤0.01% | 3949 |
|
|
2020
Q2 | $1.7M | Buy |
2,939
+20
| +0.7% | +$11.5K | ﹤0.01% | 3870 |
|
|
2020
Q1 | $1.31M | Buy |
2,919
+187
| +7% | +$169K | ﹤0.01% | 3790 |
|
|
2019
Q4 | $4.65M | Buy |
2,732
+1,857
| +212% | +$1.61M | ﹤0.01% | 3526 |
|
|
2019
Q3 | $414K | Buy |
875
+30
| +4% | +$16.3K | ﹤0.01% | 4205 |
|
|
2019
Q2 | $543K | Buy |
845
+40
| +5% | +$28.8K | ﹤0.01% | 4172 |
|
|
2019
Q1 | $658K | Buy |
805
+418
| +108% | +$338K | ﹤0.01% | 4038 |
|
|
2018
Q4 | $173K | Buy |
387
+230
| +146% | +$135K | ﹤0.01% | 4259 |
|
|
2018
Q3 | $108K | Hold |
157
| – | – | ﹤0.01% | 4446 |
|
|
2018
Q2 | $51K | Sell |
157
-3,205
| -95% | -$1.39M | ﹤0.01% | 4558 |
|
|
2018
Q1 | $1.93M | Sell |
3,362
-12
| -0.4% | -$9.52K | ﹤0.01% | 3684 |
|
|
2017
Q4 | $2.94M | Buy |
3,374
+112
| +3% | +$108K | ﹤0.01% | 3594 |
|
|
2017
Q3 | $3.23M | Buy |
3,262
+67
| +2% | +$67.1K | ﹤0.01% | 3586 |
|
|
2017
Q2 | $4.05M | Buy |
+3,195
| New | +$6.43M | ﹤0.01% | 3524 |
|
Other funds holding MTNB
HIW
SIG
TRCT
BlackRock's MTNB Position: Q2 2026 in Review
BlackRock increased its Matinas BioPharma (MTNB) stake by 1.2% in Q2 2026, buying an estimated $396 and bringing the position to 3,351 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5285.
BlackRock first reported a position in MTNB in Q2 2017 and has held it in 37 quarters since. The position peaked at $4.65M in Q4 2019. 23 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.
- BlackRock held 3,351 shares of Matinas BioPharma worth $30.8K as of Q2 2026.
- BlackRock bought 41 Matinas BioPharma shares in Q2 2026, an estimated $396.
- Matinas BioPharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5285 holding.
- BlackRock first reported a position in Matinas BioPharma in Q2 2017 and has held it in 37 quarters since.
- BlackRock's Matinas BioPharma position peaked at $4.65M in Q4 2019.
- 23 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.